# A Study Comparing the Effects of Epoetin Hospira and Epogen/Epoetin Alfa (Amgen) When Administered IV in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment

> **NCT01170078** · PHASE1 · COMPLETED · sponsor: **Hospira, now a wholly owned subsidiary of Pfizer** · enrollment: 107 (actual)

## Conditions studied

- Chronic Renal Failure

## Interventions

- **DRUG:** Epoetin Hospira
- **DRUG:** Epogen

## Key facts

- **NCT ID:** NCT01170078
- **Lead sponsor:** Hospira, now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2017-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01170078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01170078, "A Study Comparing the Effects of Epoetin Hospira and Epogen/Epoetin Alfa (Amgen) When Administered IV in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01170078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*